Patents by Inventor Wolfgang Haap

Wolfgang Haap has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250127780
    Abstract: The invention relates to a compound of formula (I) wherein L, A1, A2, R1, R2, R3, R4 and R5 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: December 18, 2024
    Publication date: April 24, 2025
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guillaume DÉCORET, Katrin GROEBKE ZBINDEN, Wolfgang HAAP, Lukas KREIS, Xavier LUCAS CABRÉ, Jean-Yves WACH, Roger WERMUTH
  • Publication number: 20250115607
    Abstract: The invention relates to a compound of formula (I) wherein A1, R1, R2, R3, R4 and R5 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: December 18, 2024
    Publication date: April 10, 2025
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guillaume DÉCORET, Katrin GROEBKE ZBINDEN, Wolfgang HAAP, Lukas KREIS, Xavier LUCAS CABRÉ, Etienne RAUBER
  • Publication number: 20240400556
    Abstract: The present invention provides compounds of formula I or II: wherein X1, X3, R1, R2, R3, R4 and R5 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula I, pharmaceutical compositions comprising them and their use as medicaments.
    Type: Application
    Filed: May 3, 2024
    Publication date: December 5, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Andrew Simon Bell, Jérémy Besnard, Anthony Richard Bradley, Luke Green, Wolfgang Haap, Buelent Kocer, Andreas Kuglstatter, Xavier Lucas, Patrizio Mattei, Dmitry Mazunin, Hasane Ratni, Claus Riemer, Willem Paul Van Hoorn
  • Publication number: 20240383875
    Abstract: The invention relates to a compound of formula (I) wherein A1, A2, A3, R1, R2, R2?, R3, R4 and R5 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: July 18, 2024
    Publication date: November 21, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Mahendra AWALE, Stefan BERCHTOLD, Julie CHARPENTIER, Héloïse Marie Albine COLOMBANO, Guillaume DECORET, Katrin GROEBKE ZBINDEN, Nicole GROSSMANN, Wolfgang HAAP, Philip Anthony HARRIS, Jérôme HERT, Jonah Milton KALLENBACH, Christian KRAMER, Lukas KREIS, Danny KRUMM, Xavier LUCAS CABRE, Nenad MANEVSKI, Philippe PFLIEGER, Amir Mohsen POURMOUSA ABKENAR, Etienne RAUBER, Dazhi TAN, Jean-Yves WACH, Roger WERMUTH
  • Publication number: 20240366581
    Abstract: The invention relates to a compound of formula (I) wherein A1, R1, R2, R3, R4 and R5 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament for treatment of indications associated with Salt-inducible kinases (SIK) such as of rheumatoid arthritis, juvenile rheumatoid arthritis, non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis, giant cell vasculitis, inflammatory bowel diseases (IBD), atherosclerosis, type 2 diabetes or glomerulonephritis.
    Type: Application
    Filed: July 18, 2024
    Publication date: November 7, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Katrin GROEBKE ZBINDEN, Wolfgang HAAP, Lukas KREIS, Kin-Chun Thomas LUK, Steven Gregory MISCHKE, Philippe PFLIEGER
  • Publication number: 20230382911
    Abstract: The present invention provides compounds of formula I or II: wherein X1, R1 and R2 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula I, pharmaceutical compositions comprising them and their use as medicaments.
    Type: Application
    Filed: July 28, 2023
    Publication date: November 30, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Andrew Simon BELL, Jérémy BESNARD, Anthony Richard BRADLEY, Luke GREEN, Wolfgang HAAP, Buelent KOCER, Andreas KUGLSTATTER, Xavier LUCAS, Patrizio MATTEI, Dmitry MAZUNIN, Claus RIEMER, Willem Paul VAN HOORN
  • Publication number: 20230227449
    Abstract: The present invention provides compounds of formula I or II: wherein X1, X3, R1, R2, R3, R4 and R5 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula I, pharmaceutical compositions comprising them and their use as medicaments.
    Type: Application
    Filed: December 19, 2022
    Publication date: July 20, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Andrew Simon Bell, Jérémy Besnard, Anthony Richard Bradley, Luke Green, Wolfgang Haap, Buelent Kocer, Andreas Kuglstatter, Xavier Lucas, Patrizio Mattei, Dmitry Mazunin, Hasane Ratni, Claus Riemer, Willem Paul Van Hoorn
  • Publication number: 20230219953
    Abstract: The present invention provides compounds of formula I wherein X1, X2, X3, X4, R1, R1a, R1b, R2?, R2?, R3?, R3?, R6 and R7 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula I, pharmaceutical compositions comprising them and their use as medicaments.
    Type: Application
    Filed: December 19, 2022
    Publication date: July 13, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Andrew Simon Bell, Jérémy Besnard, Anthony Richard Bradley, Luke Green, Wolfgang Haap, Buelent Kocer, Andreas Kuglstatter, Xavier Lucas, Patrizio Mattei, Dmitry Mazunin, Claus Riemer, Willem Paul Van Hoorn
  • Publication number: 20220298152
    Abstract: The present invention provides a compound of formula I having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compound of the present invention is useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Application
    Filed: June 2, 2022
    Publication date: September 22, 2022
    Inventors: Wolfgang HAAP, Thomas WOLTERING
  • Patent number: 11034687
    Abstract: The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: June 15, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Ulrike Obst Sander, Jens-Uwe Peters, Thomas Woltering
  • Publication number: 20210101894
    Abstract: The present invention provides a compound of formula I having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compound of the present invention is useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Application
    Filed: December 16, 2020
    Publication date: April 8, 2021
    Inventors: Wolfgang HAAP, Thomas WOLTERING
  • Patent number: 10829500
    Abstract: The present invention provides a compound of formula I having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: November 10, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Andreas Kuglstatter, Ulrike Obst Sander, Jens-Uwe Peters, Mark Rogers-Evans, Thomas Woltering, Christian Schnider, Roger Wermuth
  • Publication number: 20200308166
    Abstract: The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Application
    Filed: June 17, 2020
    Publication date: October 1, 2020
    Inventors: Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Ulrike Obst Sander, Jens-Uwe Peters, Thomas Woltering
  • Patent number: 10723729
    Abstract: The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: July 28, 2020
    Assignee: Hoffmann-Le Roche Inc.
    Inventors: Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Ulrike Obst Sander, Jens-Uwe Peters, Thomas Woltering
  • Patent number: 10696691
    Abstract: The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: June 30, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Ulrike Obst Sander, Walter Vifian, Thomas Woltering
  • Patent number: 10689339
    Abstract: The invention relates to a compound of formula (I) wherein R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: June 23, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Wolfgang Haap, Bernd Kuhn, Thomas Luebbers, Jens-Uwe Peters
  • Publication number: 20190352312
    Abstract: The present invention provides a compound of formula I having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Application
    Filed: July 31, 2019
    Publication date: November 21, 2019
    Inventors: Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Andreas Kuglstatter, Ulrike Obst Sander, Jens-Uwe Peters, Mark Rogers-Evans, Thomas Woltering, Christian Schnider, Roger Wermuth
  • Publication number: 20190337936
    Abstract: The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Application
    Filed: July 16, 2019
    Publication date: November 7, 2019
    Inventors: Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Ulrike Obst Sander, Jens-Uwe Peters, Thomas Woltering
  • Publication number: 20190307737
    Abstract: The invention relates to a compound of formula (I) wherein A1, A2 and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: November 2, 2018
    Publication date: October 10, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Wolfgang Haap, Holger Kuehne, Harald Mauser
  • Patent number: 10414780
    Abstract: The present invention provides a compound of formula I having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: September 17, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Andreas Kuglstatter, Ulrike Obst Sander, Jens-Uwe Peters, Mark Rogers-Evans, Thomas Woltering, Christian Schnider, Roger Wermuth